S1PR1

(redirected from S1P1)

S1PR1

A gene on chromosome 1p21 that encodes an EDG (endothelial differentiation, G protein-coupled) family receptor, which is highly expressed in endothelial cells. It binds the sphingosine-1-phosphate with high affinity and high specificity, and may be involved in regulating endothelial cell differentiation. Receptor activation induces cell–cell adhesion.
Mentioned in ?
References in periodicals archive ?
Epix") announced today that AMG 277 discriminates against S1P3 receptor by 50-fold and that the S1P1 lead compounds will be offered December 8, 2011 in a sealed bid sale.
It binds to S1P1 receptors on lymphocytes, inducing internalization of receptors.
For example, S1P1 means a solution with SA 1 wt% and PEO 1 wt%.
Gujrathi will assume leadership of the RPC1063 clinical program, and will also lead expansion of development activities for both the S1P1 agonist portfolio as well as additional assets in the immunology therapeutic area that the company will in-license in accordance with its strategic plan.
Epix") announced today that AMG 369 discriminates against S1P3 receptor by 296-fold and that the S1P1 lead compounds, including AMG 369, will be offered December 8, 2011 in a sealed bid sale.
Clearly our forward focus in the RPC1063 clinical program will be to provide meaningful product candidate differentiation to serve the multiple sclerosis market with this potentially best-in-class S1P1 agonist.
The S1P1 program is supported by the company's recently determined high-resolution protein crystal structure of the S1P1 receptor.
Trial results show novel S1P1 modulator produced strong, dose-dependent lymphocyte lowering -
Epix"), announced today that the back-up compounds and S1P1 lead compounds, assets generated by Epix Pharmaceuticals, Inc.
The S1P1 program is supported by the company's recently determined and proprietary high resolution protein crystal structure of the S1P1 receptor.
Initiated enrollment in a Phase 1 multiple-ascending dose trial of APD334, Arena's S1P1 receptor agonist intended for the treatment of autoimmune diseases.